NASDAQ
08.08.25 | 16:29
47,500 US-Dollar
-0,90 % -0,430
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Tarsus targets 95,000-100,000 bottles for Q3 2025 amid accelerated XDEMVY launch momentum | 1 | Seeking Alpha | ||
| TARSUS PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| Mi | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | 51 | GlobeNewswire (Europe) | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
| Mi | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| Mi | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Tarsus Pharmaceuticals, Inc: Tarsus to Report Second Quarter 2025 Financial Results on Wednesday, August 6, 2025 | 1 | GlobeNewswire (USA) | ||
| 18.06. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 09.06. | Tarsus Pharmaceuticals auf Goldman Sachs Konferenz: Fokus auf strategisches Wachstum | 3 | Investing.com Deutsch | ||
| 02.06. | Oppenheimer assumes Tarsus stock at outperform on strong sales | 1 | Investing.com | ||
| 27.05. | Tarsus Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) | 2 | Benzinga.com | ||
| 27.05. | H.C. Wainwright sets $72 target for Tarsus stock with Buy rating | 2 | Investing.com | ||
| 06.05. | 6 Analysts Assess Tarsus Pharmaceuticals: What You Need To Know | 2 | Benzinga.com | ||
| 02.05. | Tarsus Pharmaceuticals anticipates 85,000-90,000 XDEMVY bottles dispensed in Q2 2025 amid expanded DTC campaign | 1 | Seeking Alpha | ||
| 01.05. | Tarsus Pharmaceuticals, Inc. GAAP EPS of -$0.64, revenue of $78.3M | 3 | Seeking Alpha | ||
| 01.05. | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | 503 | GlobeNewswire (Europe) | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| 01.05. | Tarsus Pharmaceuticals, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 01.05. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 30.04. | An Overview of Tarsus Pharmaceuticals' Earnings | 2 | Benzinga.com | ||
| 24.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025 | 1 | GlobeNewswire (USA) | ||
| 22.04. | Tarsus Pharmaceuticals, Inc: Tarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 ... | 1 | GlobeNewswire (USA) | ||
| 13.03. | Tarsus Pharmaceuticals, Inc. - 8-K, Current Report | 1 | SEC Filings |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 6,822 | +2,00 % | Evotecs Turnaround, Veganz Groups Rekordjahr, Pumas Neustart: Ihr Profit-Fahrplan durch die Marktwende! | Deutschlands Aktienmarkt zeigt sich im Juli 2025 extrem polarisiert. Während manche Schwergewichte straucheln glänzen andere mit Rekorden. Diese Volatilität speist sich aus Zinsängsten, disruptiven... ► Artikel lesen | |
| MODERNA | 22,555 | -1,25 % | Ihre wichtigsten Termine: Alle Blicke auf: Moderna, Chevron, Daimler Truck, Snap und Colgate-Palmolive | © Foto: Rishi Deka/ZUMA Press Wire/dpaGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine... ► Artikel lesen | |
| VIKING THERAPEUTICS | 32,320 | +5,98 % | Eli Lilly's obesity drug data lifts Viking Therapeutics stock | ||
| SCORPIUS | 0,072 | 0,00 % | Scorpius Holdings, Inc.: Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia | Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX, May 04, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| KUROS BIOSCIENCES | 28,500 | -1,38 % | Kuros Biosciences AG: Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance | Kuros Biosciences launches MagnetOs MIS Delivery System by completing first cases, and continues global expansion with incremental Brazil clearance
Schlieren (Zürich), Switzerland, August 5... ► Artikel lesen | |
| ABIVAX | 60,00 | 0,00 % | Abivax, CRISPR Therapeutics und Revolution Medicines: Biotech im Höhenflug - das wikifolio ... | ||
| RELIEF THERAPEUTICS | 2,635 | -0,19 % | Adhoc: Relief Therapeutics Holding SA: Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze | Relief Therapeutics Holding SA / Key word(s): Mergers & Acquisitions
Relief Therapeutics Announces Proposed Business Combination with NeuroX, successor to MindMaze
29-Jul-2025 / 07:00 CET/CEST
Release... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 1,852 | -18,38 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Financial Results and Corporate Updates for Second Quarter and First Half 2025 | $60.0M in 2Q25 Total Product Revenue More than 100 Patients Treated with Amtagvi® in 2Q25 Strategic Restructuring Extends Cash Runway into 4Q26 FY25 Total Product Revenue Guidance of $250M-$300M Reiterated... ► Artikel lesen | |
| DENALI THERAPEUTICS | 12,185 | -0,25 % | Denali Therapeutics Inc.: Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome | SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2025, and provided business... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 1,829 | +2,70 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update | - May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,551 | -3,95 % | Rocket Pharmaceuticals: Jefferies hebt Kursziel an, bleibt aber bei "Hold" | ||
| SYNDAX PHARMACEUTICALS | 10,600 | -3,64 % | Syndax Pharmaceuticals, Inc.: Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August... ► Artikel lesen | |
| ASCENDIS PHARMA | 165,00 | +1,23 % | Ascendis Pharma: RBC erhöht Kursziel auf 230 $ wegen starkem Yorvipath-Wachstum | ||
| JASPER THERAPEUTICS | 2,680 | -1,83 % | Jasper Therapeutics, Inc.: Jasper Therapeutics Announces Corporate Reorganization and Other Cost Cutting Measures to Extend Cash Runway | Reducing workforce by approximately 50% to focus on Chronic Urticaria programs and extend cash runway Dr. Edwin Tucker departing as Chief Medical Officer; Dr. Daniel Adelman to serve as Acting Chief... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,240 | +0,71 % | Arcutis outlines sustained ZORYVE growth with 28% sequential revenue expansion and eyes cash flow breakeven in 2026 |
TARSUS PHARMACEUTICALS INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,430 (-0,90 %) liegt der Kurs bei 47,500 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu TARSUS PHARMACEUTICALS INC finden Sie auf Wallstreet Online.